Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
How would you approach the management of a women who was incidentally found to have a deeply invasive low-grade endometrial carcinoma after she underwent a supracervical hysterectomy with placement of mesh for uterine prolapse?
Related Questions
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
Would you consider the addition of trastuzumab to carboplatin/paclitaxel for an advanced uterine carcinosarcoma that stains HER2 IHC 3+ in the carcinomatous components but IHC 0 in the sarcomatous regions?
For a patient with IIIC endometrial adenocarcinoma diagnosed and treated with 6 cycles of Carboplatin/Paclitaxel two years prior, would you consider maintenance therapy with PD-L1 inhibition, given results of GY018 and RUBY?
How would you manage a patient in her 50s with FIGO IA clear cell carcinoma of the endometrium with extensive LVSI and ITCs in an obturator node after 6 cycles of carbo/taxol?
Would you incorporate a PARP inhibitor into the management of a patient with endometrial cancer with a germline or somatic BRCA mutation?
Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)?
What is your preferred method of endometrial sampling during medical management of endometrial cancer?
Is it ever acceptable to treat low pelvis (vs. whole pelvis) for an early vaginal recurrence of endometrial cancer?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
Do you add pelvic RT for stage II gr 2 endometrial cancers with multiple high risk features?